Lobeglitazone/metformin - Chong Kun Dang

Drug Profile

Lobeglitazone/metformin - Chong Kun Dang

Alternative Names: CKD 395; Lobeglitazone sulfate/metformin hydrochloride - Chong Kun Dang

Latest Information Update: 17 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chong Kun Dang
  • Class Antihyperglycaemics; Biguanides; Piperidines; Small molecules; Thiazolidinediones
  • Mechanism of Action AMP activated protein kinase stimulants; Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Type 2 diabetes mellitus

Most Recent Events

  • 01 Nov 2015 Chong Kun Dang Pharmaceutical completes a pharmacokinetics phase I trial in Healthy volunteers in South Korea (PO) (NCT02648854)
  • 01 Oct 2015 Chong Kun Dang Pharmaceutical initiates a pharmacokinetics phase I trial in Healthy volunteers in South Korea (PO) (NCT02648854)
  • 01 Aug 2015 Chong Kun Dang completes a phase I trial in Healthy volunteers in South Korea (NCT02565368)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top